Positive Phase IIb CONTROL study evaluating TMB-001

Shares of Timber Pharmaceuticals (NYSE American: TMBR) rose as much as 14% to $0.41 yesterday, after the rare and orphan dermatologic diseases announced a late-breaking presentation of a sub-analysis of the Phase IIb CONTROL study that evaluated TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, at the American Academy of Dermatology (AAD) 2022 Annual Meeting being held in Boston, MA, from March 25-29.

The presentation by Dr Christopher Bunick, Yale University School of Medicine, demonstrated that patients achieved treatment success with TMB-001 regardless of the subtype of congenital ichthyosis (CI).

“We know that the treatment of CI is a clear unmet need in dermatology as there are currently limited options available,” said Drd Bunick, adding: “Our goal with this analysis of the previously completed Phase IIb CONTROL study was to assess whether primary efficacy results for TMB-001 differed by CI subtype, and the results are encouraging for people who are living with even the most severe forms of the disease.”